Harnessing the Therapeutic Potential of Decoys in Non-Atherosclerotic Cardiovascular Diseases: State of the Art.
Maryam Mahjoubin-TehranStephen L AtkinEvgeny E BezsonovTannaz JamialahmadiAmir Hossein SahebkarPublished in: Journal of cardiovascular development and disease (2021)
Cardiovascular disease (CVD) is the main cause of global death, highlighting the fact that conventional therapeutic approaches for the treatment of CVD patients are insufficient, and there is a need to develop new therapeutic approaches. In recent years, decoy technology, decoy oligodeoxynucleotides (ODN), and decoy peptides show promising results for the future treatment of CVDs. Decoy ODN inhibits transcription by binding to the transcriptional factor, while decoy peptide neutralizes receptors by binding to the ligands. This review focused on studies that have investigated the effects of decoy ODN and decoy peptides on non-atherosclerotic CVD.
Keyphrases
- cardiovascular disease
- end stage renal disease
- transcription factor
- ejection fraction
- type diabetes
- chronic kidney disease
- newly diagnosed
- gene expression
- prognostic factors
- coronary artery disease
- machine learning
- amino acid
- cardiovascular events
- mass spectrometry
- current status
- replacement therapy
- patient reported outcomes